The venture arm associated with XTX Markets, backing technical founders from seed through Series B and beyond across AI infrastructure, healthcare, enterprise software, financial markets and physical-world applications.
Founded —
Type Venture capital 0 No funds on record yet.
No team members on record yet.
team@apexlogos.ai · 8 hours ago
Investment-fund research reviewed 2026-10-06. Publicly identified funds, dates, amounts and fundraising status are below. Undisclosed commitments remain unknown; this is not a complete register of private SPVs or parallel entities.
Fund size, capital structure and stages
| Field | Finding | Evidence and qualification |
| --- | --- | --- |
| Latest identifiable dedicated fund/vintage, target or final close | **Missing: no independently verified dedicated fund size or close announcement found.** | Current official venture page does not disclose a fund amount: https://www.xtxmarkets.com/ventures/ (undated). Original https://www.xtxventures.com/ redirects there. Corporate-arm identity alone does not prove a particular balance-sheet budget or evergreen structure. |
| Total venture AUM or deployment budget | **Missing.** | No reliable amount found in checked official or reporting sources. Parent trading activity and philanthropic funds must not be treated as venture AUM. |
| Conflicting directory figures | **Unverified; do not import.** Shizune says $9.6m with July 2024 “last fund”; Goldilocks says $2bn. | https://shizune.co/investors/profile/xtx-ventures (undated; states updated September 2026) and https://goldi.ai/intelligence/vc/xtx-ventures (states updated 2026-05-04). Neither supplies a supporting named fund-close announcement; material disagreement is unresolved. |
| Check sizes | **Missing from verified firm evidence.** | Shizune's $2m–$7.6m Seed and $6m–$60m Series A bands are explicitly round-size percentiles, not individual XTX checks. Signal's Perrin range is his current profile, not a verified XTX mandate. |
| Current strategy | **Seed–Series B and beyond**, focused on AI/ML technical founders, from product validation toward scale. | Official https://www.xtxmarkets.com/ventures/ (undated). Sectors include infrastructure, healthcare, enterprise software and financial markets. |
| Historical stage evidence | Seed, Series A, Series B, Series C, Series D; participation and leading both evidenced. | Oriole Seed/Series A, Terray Series B, Groq Series C and X-energy Series D announcements below. These do not establish identical appetite for every new prospective investment. |
Older directory descriptions say Seed–Series A, while the current official page extends through Series B and beyond. Prefer the current primary mandate. Oriole's 2024 announcement says XTX can lead or co-invest with dedicated follow-on capital; no amount is given. https://oriolenetworks.com/oriole-networks-raises-22m/ (2024-10-21).
Funds recorded in Adex after this review:
No independently verifiable standalone fund recorded for this entity; see the research findings above. SHOW MORE
team@apexlogos.ai · 9 hours ago
Match research 2026-10-06 / XTXVentures / sha256:4dbb1c54d005a443e6dc91cfd507a98dd8bb2760269f5ee9ca9391565ab582ee / part 2 of 2
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
| **X-energy** | Advanced nuclear reactors and fuel; energy deep tech. | XTX Ventures explicitly named a new investor in approximately $700m Series D closed and announced 2025-11-24, led by Jane Street. XTX check undisclosed. | Company primary https://x-energy.com/news/x-energy-closes-oversubscribed-700-million-series-d-financing-round-to-continue-expansion-to-meet-global-energy-demand/ (2025-11-24). |
| **Prior Labs** | Research-derived tabular foundation models, including TabPFN; AI-model deep tech rather than generic enterprise SaaS. | Company identifies XTX Ventures as a backer; Axios reports €9m pre-seed led by Balderton in February 2025 with XTX participating. Check undisclosed. | Company primary https://priorlabs.ai/case-studies/oxcan (publication date not established; undated); reputable reporting https://www.axios.com/newsletters/axios-pro-rata-789f88d5-a109-4e81-95fd-9e5cfef70c70 (February 2025; precise day not established from retrieved excerpt). |
| **Tenstorrent — parent attribution caveat** | AI processors and RISC-V IP; semiconductor deep tech. | Official 2024-12-02 release names **XTX Markets**, with its CTO quoted, in >$693m Series D at $2bn pre-money valuation. Supports XTX-group investment but exact venture-arm entity remains uncertain. | https://tenstorrent.com/newsroom/tenstorrent-closes-693m-of-series-d-funding-led-by-samsung-securities-and-afw-partners (2024-12-02). Do not assign the unrelated $100m August 2023 round to XTX based on this later participation. |
| **Anthropic — attribution not independently primary-confirmed** | Foundation-model research and AI safety; AI deep tech. | Adex baseline plus former XTX head's Signal history/HEC biography indicate an XTX investment. Signal connects Perrin to May 2023 $450m Series C. Company's Series C announcement verifies the round but does **not explicitly name XTX**. Therefore investment is plausible, not primary-round verified here. | https://www.anthropic.com/news/anthropic-series-c (2023-05-23); https://signal.nfx.com/investors/alexandre-perrin (undated); self-reported alumni biography https://www.hecalumni.fr/en/cv/alexandre-perrin/hec/2014 (undated). Preserve distinction between round confirmation and investor confirmation. |
## Previous neurotech investments
### BIOS Health — directly verified neurotechnology
BIOS develops neural-data/AI technology for precision medicine of the nervous system and bioelectronic therapies. This is **direct neurotech**, including machine-learning neural interfaces; it is not merely a general digital-health business. Company's 2023-06-22 announcement explicitly names **XTX Ventures** among major institutional investors and quotes XTX Markets treasury leadership. Source: https://www.bios.health/bios-fundraise-press-release-6-23 (2023-06-22). Reputable independent reporting corroborates participation and says the amount was **undisclosed**: https://siliconcanals.com/bios-health-raises-finding/ (2023-06-23, updated 2024-03-25).
**Stage/amount uncertainty:** Signal's former-head profile labels June 2023 as $20m Series A; primary announcement calls it a closed venture round without disclosing size or stage. Do not silently import $20m or Series A as verified. XTX's individual investment amount and lead status are unknown. A London Stock Exchange-hosted company showcase lists XTX Ventures as a current investor and describes neural reading/writing technology, supporting continued attribution: https://docs.londonstockexchange.com/sites/default/files/documents/240607-health-tech-showcase-brochure.pdf (June 2024, exact publication day not established; filename suggests 2024-06-07). Its £27.4m cumulative funding combines VC and non-dilutive funding; its £25m+ growth round is a fundraising proposal, not proof of a completed round. BIOS is absent from the supplied Adex investment list: a later reviewer should prioritize this verified omission.
### BlueSkeye AI — verified adjacent mental-health/affective computing
XTX Ventures led a **£3.4m Seed** financing in October 2022. BlueSkeye analyzes face and voice behavior with machine learning for mental-health and behavioral measurements. This supports a mental-health/digital-biomarker and affective-computing track record; the checked sources do not show direct neural recording, stimulation or a brain interface. Primary university venture source: https://www.nottinghamtechventures.com/companies/blueskeye-ai/ (undated). Transaction counsel: https://www.marriottharrison.com/xtx-ventures-led-a-3-4-million-funding-round-into-university-of-nottingham-spinout-blueskeye-ai (2022-11-07). Co-investor Foresight release dated **2022-10-31** gives £3.4m joint financing and separately **£600k from Foresight**, which must not become XTX's check: https://media.umbraco.io/foresight/sb5kb45i/foresight-meif-pr-blueskeye-final-31-10-22.pdf . XTX check undisclosed.
No additional direct neurotech investment was verified in the sources checked. This is not evidence that BIOS is the firm's only such investment. Healthcare/medical imaging, AI drug discovery and personal Gerko investments should not automatically receive a neurotech classification.
## Gaps, conflicts and later Adex review notes
1. No Adex records were changed. This file is a research handoff only.
2. Current firm homepage no longer displays the 37-company portfolio claimed in Adex's 2026-09-14 homepage evidence. The earlier claim may have been accurate when captured, but the current page cannot independently substantiate the full list. Unverified baseline names above remain leads, not disproved investments.
3. Fund size, fund vintage, target/final close, venture AUM, investment budget and check range remain **unknown**. Resolve conflicting $9.6m/$2bn directories through a dated primary announcement or firm response before any later update. Company round totals cannot fill these fields.
4. Add/review BIOS Health attribution only in a separately authorized future update; official June 2023 evidence is strong, but stage and round/check amounts remain unresolved.
5. Adex's existing `isLead: false` rows are baseline values, not proof of non-lead status: Oriole Seed and BlueSkeye Seed have explicit lead/co-lead evidence. Likewise existing missing dates can be researched against the announcements here, preserving announcement versus close dates.
6. Keep Tenstorrent's **XTX Markets** legal-entity wording; do not merge parent and venture arm without evidence. Keep Anthropic's attribution caveat and do not treat Signal partner histories as primary corporate proof.
7. Scope is selected documented examples and targeted neurotech/fund searches, not an exhaustive audit of every portfolio company or every financing. Check newer announcements before asserting any 2024/2025 transaction is the company's latest. Sources do not establish the latest fund, so no “latest fund” claim is made. SHOW MORE
team@apexlogos.ai · 9 hours ago
Match research 2026-10-06 / XTXVentures / sha256:4dbb1c54d005a443e6dc91cfd507a98dd8bb2760269f5ee9ca9391565ab582ee / part 1 of 2
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
# XTX Ventures research
- Exact Adex ID: `XTXVentures`
- Adex URL: https://adex.page/firms/XTXVentures
- Research date: 2026-10-06
- Status: complete for the scoped public-source research; preliminary baseline was saved before external verification. No Adex mutations.
## Existing Adex baseline
Read-only MCP Search snapshot: `data/research/_sources/XTXVentures.adex.json`, retrieved 2026-10-06T19:28:51.133Z. Firm description: The venture arm associated with XTX Markets, backing technical founders from seed through Series B and beyond across AI infrastructure, healthcare, enterprise software, financial markets and physical-world applications.
Adex records 37 investments, sourced to the firm homepage with research date 2026-09-14; all round dates, round amounts and checks are missing. Named companies: Anthropic, Flapping Airplanes, Groq, Harmattan, Prior Labs, Tenstorrent, VAST Data, Wayve AI, X-energy, BlueSkeyeAI, Cinemersive, Cloud NC, Corintis, Crossover Markets, DiA Imaging Analysis, dModel, Eko Health, Ethos, Exactly.ai, Gladia, IBEX, iGent AI, Logos, Lucida Medical, Oriole Networks, Qureight, ReSim, Solve Chemistry, Sphotonix, Standard Nuclear, Subterra, SWAPP, Sylph, Terray Therapeutics, TraceAir, Turbine, Verax AI. Treat these as baseline claims awaiting verification. Fund size and check ranges are missing.
NFX Signal baseline URL: https://signal.nfx.com/firms/xtx-ventures
## Verified summary and identity
Research completed 2026-10-06. XTX Ventures is the venture arm of algorithmic trading firm XTX Markets. Current official mandate is Seed through Series B and beyond, backing technical AI/ML founders; historical transactions include Series C and Series D. A directly verified neurotech investment is **BIOS Health**. **BlueSkeye AI** is a verified mental-health/affective-computing investment adjacent to neurotech, rather than a neural-interface investment. Other verified deep-tech examples include Groq, Oriole Networks, Terray Therapeutics and X-energy. Tenstorrent's official release attributes investment to **XTX Markets**, requiring legal-entity review before assigning its round to XTX Ventures.
All sources below were checked/accessed 2026-10-06. Dates shown refer to publication or announcement dates, not necessarily legal closing dates. Technology classifications are research judgments based on cited descriptions. Company financing totals are not XTX checks or XTX fund sizes.
## NFX Signal starting evidence
- Baseline firm profile https://signal.nfx.com/firms/xtx-ventures could not be retrieved by the browsing tool (inaccessible/internal error). No current fund-size or check-size value can be established from that page.
- Related former Head of Ventures Alexandre Perrin profile was directly accessible: https://signal.nfx.com/investors/alexandre-perrin (undated). It lists XTX Markets tenure 2021–2023 and historical BIOS, Anthropic and Terray investments, including BIOS described as a June 2023 Series A of $20m. This is a useful discovery source, not independent proof of firm attribution or round size. Its current affiliation is displayed inconsistently as Cleverton Ventures on the direct page and Enauto Ventures in an indexed result; its $200k–$2m investment range belongs to the current individual profile and must not be imported as XTX Ventures' range.
- Founder Alexander Gerko profile https://signal.nfx.com/investors/alexander-gerko (undated; search-index accessible) lists personal investments such as Boom Supersonic and Revolve Robotics. These cannot be assigned to the venture arm merely because he founded XTX Markets.
## Fund size, capital structure and stages
| Field | Finding | Evidence and qualification |
| --- | --- | --- |
| Latest identifiable dedicated fund/vintage, target or final close | **Missing: no independently verified dedicated fund size or close announcement found.** | Current official venture page does not disclose a fund amount: https://www.xtxmarkets.com/ventures/ (undated). Original https://www.xtxventures.com/ redirects there. Corporate-arm identity alone does not prove a particular balance-sheet budget or evergreen structure. |
| Total venture AUM or deployment budget | **Missing.** | No reliable amount found in checked official or reporting sources. Parent trading activity and philanthropic funds must not be treated as venture AUM. |
| Conflicting directory figures | **Unverified; do not import.** Shizune says $9.6m with July 2024 “last fund”; Goldilocks says $2bn. | https://shizune.co/investors/profile/xtx-ventures (undated; states updated September 2026) and https://goldi.ai/intelligence/vc/xtx-ventures (states updated 2026-05-04). Neither supplies a supporting named fund-close announcement; material disagreement is unresolved. |
| Check sizes | **Missing from verified firm evidence.** | Shizune's $2m–$7.6m Seed and $6m–$60m Series A bands are explicitly round-size percentiles, not individual XTX checks. Signal's Perrin range is his current profile, not a verified XTX mandate. |
| Current strategy | **Seed–Series B and beyond**, focused on AI/ML technical founders, from product validation toward scale. | Official https://www.xtxmarkets.com/ventures/ (undated). Sectors include infrastructure, healthcare, enterprise software and financial markets. |
| Historical stage evidence | Seed, Series A, Series B, Series C, Series D; participation and leading both evidenced. | Oriole Seed/Series A, Terray Series B, Groq Series C and X-energy Series D announcements below. These do not establish identical appetite for every new prospective investment. |
Older directory descriptions say Seed–Series A, while the current official page extends through Series B and beyond. Prefer the current primary mandate. Oriole's 2024 announcement says XTX can lead or co-invest with dedicated follow-on capital; no amount is given. https://oriolenetworks.com/oriole-networks-raises-22m/ (2024-10-21).
## Previous deep-tech investments with verified attribution
| Company | Technology and classification | Investment evidence, stage/date and amount | Supporting sources |
| --- | --- | --- | --- |
| **Groq** | Specialized AI compute/silicon; direct hardware deep tech. | XTX Ventures participated as an existing investor in $300m Series C, closed/reported 2021-04-14. XTX's check is undisclosed. | Official announcement URL https://groq.com/groq-closes-300-million-fundraise/ redirects to https://groq.com/newsroom/groq-closes-300-million-fundraise ; extraction was intermittent and did not yield reliable attribution text. Attribution and date independently confirmed by https://www.marketscreener.com/quote/stock/GCM-GROSVENOR-INC-115395155/news/Groq-Inc-announced-that-it-has-received-300-million-in-funding-from-a-group-of-investors-33441509/ (2021-04-14) and reputable corporate-venture reporting https://globalventuring.com/content/uploads/2021/05/GCV-May-2021.pdf (May 2021). |
| **Oriole Networks** | UCL-origin optical/photonic networking connecting AI accelerators; hardware and research-derived IP. | XTX Ventures co-led £10m Seed announced 2024-03-27 and reinvested in $22m Series A announced 2024-10-21. Individual checks undisclosed. | Co-investor primary https://www.cleangrowthfund.com/news/cgf-invests-in-10m-seed-round-of-oriole-networks/ (2024-03-27); company primary https://oriolenetworks.com/oriole-networks-raises-22m/ (2024-10-21); transaction counsel https://www.michelmores.com/corporate-news/michelmores-advise-tech-start-up-oriole-networks-on-10m-ai-raise/ (2024-03-28); reporting https://tech.eu/2024/03/28/oriole-raises-10m-seed-to-reduce-ai-s-energy-consumption (2024-03-28). Company URL slug says “22m”/search title used pounds, but body explicitly says **$22m**; counsel reports equivalent **£17.5m**, https://www.michelmores.com/corporate-news/michelmores-advises-photonic-start-up-oriole-networks-on-17-5m-series-round-a-led-by-plural/ (2024-10-22). |
| **Terray Therapeutics** | Generative AI plus proprietary scaled experimental chemistry data for small-molecule drug discovery; computational biology/chemistry deep tech, **not verified neurotech**. | XTX Ventures named among participants in $120m Series B announced 2024-10-17. | Company primary https://www.terraytx.ai/press/terray-therapeutics-closes-oversubscribed-120m-series-b-to-advance-its-generative-ai-pipeline-of-small-molecule-therapeutics-to-the-clinic (2024-10-17); independently https://www.axios.com/newsletters/axios-pro-rata-23370f81-de26-4af8-b9a4-ee5e3875fc5e (2024-10-18). | SHOW MORE
team@apexlogos.ai · 22 days ago
MATCH 
David Grimm
Oriole Networks$22M · 2024-10-21
AlbionVC
Ian Hogarth
Plural
TDK Ventures
Groq$300M · 2021-04-14
